Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform Long: Cell membrane Single-pass type I membrane protein Extracellular side Note=Localized at the cell surface of melanoma cells.; SUBCELLULAR LOCATION: Isoform Short: Secreted, extracellular space, extracellular matrix. Cell surface. Note=Localized at the cell surface of melanoma cells. |
Domain |
PF11857 Domain of unknown function (DUF3377) PF00045 Hemopexin PF00413 Matrixin PF01471 Putative peptidoglycan binding domain |
Function |
Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells. |
Biological Process |
GO:0001501 skeletal system development GO:0001503 ossification GO:0001958 endochondral ossification GO:0016485 protein processing GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030574 collagen catabolic process GO:0032963 collagen metabolic process GO:0035988 chondrocyte proliferation GO:0036075 replacement ossification GO:0043062 extracellular structure organization GO:0044236 multicellular organism metabolic process GO:0044243 multicellular organism catabolic process GO:0044259 multicellular organismal macromolecule metabolic process GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048701 embryonic cranial skeleton morphogenesis GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0051604 protein maturation GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060350 endochondral bone morphogenesis GO:0097094 craniofacial suture morphogenesis GO:1904888 cranial skeletal system development |
Molecular Function |
GO:0004175 endopeptidase activity GO:0004177 aminopeptidase activity GO:0004222 metalloendopeptidase activity GO:0008047 enzyme activator activity GO:0008235 metalloexopeptidase activity GO:0008237 metallopeptidase activity GO:0008238 exopeptidase activity GO:0070006 metalloaminopeptidase activity |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005796 Golgi lumen |
KEGG | - |
Reactome |
R-HSA-1592389: Activation of Matrix Metalloproteinases R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1474244: Extracellular matrix organization |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MMP16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MMP16 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MMP16 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MMP16 in various data sets.
|
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP16. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MMP16 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MMP16 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MMP16 |
Name | matrix metallopeptidase 16 (membrane-inserted) |
Aliases | MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ...... |
Chromosomal Location | 8q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MMP16 collected from DrugBank database. |
Details on drugs targeting MMP16.
|